Skip to content
Medical Health Aged Care, Seniors Interest

Being embedded and on-site enhances pharmacists’ quality use of medicines activities at aged care facilities

Monash University 2 mins read

A new study by Monash University suggests being on-site and truly embedded within the interprofessional aged care team provides greater opportunities to support resident- and system-level improvements in quality use of medications. 

In 2022 the Australian Government announced a national rollout of embedded on-site pharmacists in all Government funded residential aged care facilities (RACFs). This was in direct response to recommendations from the 2019 Royal Commission into Aged Care Quality and Safety, and builds on evidence from national and international studies. While the details of the model are yet to be finalised, it is anticipated that the phased roll-out of this new workforce model will now commence in 2024. 

The new study by the Centre for Medicine Use and Safety (CMUS) at the Monash Institute of Pharmaceutical Sciences (MIPS) and published in the Australasian Journal on Ageing, set out to explore the roles of early adopters of Australia’s embedded on-site pharmacist model in supporting quality use of medications in RACFs.

Lead author Dr Amanda Cross, a pharmacist and Research Fellow at CMUS, interviewed 15 pharmacists from around Australia who were early adopters of the embedded onsite aged care pharmacist model. 

“It was evident from the early adopters of this model that being embedded and onsite was important for being able to be an advocate for the resident, build enhanced relationships with the interdisciplinary team, and drive system-level improvements in medication management,” Dr Cross said.

The study highlights both resident-level roles (e.g. actively contributing to collaborative outcome-focused resident-centred care) and system-level roles (e.g. leading clinical governance and quality improvement processes). The system-level roles were consistent with that of a knowledge broker, an individual who helps to move evidence and guidelines into local practice. 

Dr Cross says, “This system-level knowledge broker role can serve as a framework to help guide the new aged care pharmacist model. Pharmacists acting as knowledge brokers can help to improve policies and processes, link key stakeholders and build the capacity of individuals and the aged care provider organisations to support quality use of medications.” 

Dr Cross and colleagues at CMUS are currently working on two Medical Research Future Fund projects investigating the role of embedded on-site pharmacists working as knowledge brokers in residential aged care. This includes implementing the new CMUS-led Australian Clinical Practice Guidelines for the Appropriate Use of Psychotropic Medications in People Living with Dementia and in Residential Aged Care. 

CMUS Director Professor Simon Bell said “the study provides important insights into new resident- and system-level roles for pharmacists and the corresponding competencies that will be required.” 

The full paper has been published in the Australasian Journal on Ageing and can be read here https://onlinelibrary.wiley.com/doi/10.1111/ajag.13254   

Ends


Contact details:

Kate Carthew - Media and Communications Manager
E: kate.carthew@monash.edu
T: +61 (0) 438 674 814

Media

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.